Multisystem Inflammatory Syndrome in a Young Adult (MIC-A) Following SARS-CoV-2 Infection

Medicina (Kaunas). 2022 Oct 24;58(11):1515. doi: 10.3390/medicina58111515.

Abstract

Multisystem Inflammatory Syndrome (MIS) is a rare but increasingly recognized complication of SARS-CoV-2 infection, usually presenting 2 to 6 weeks after the onset of COVID-19 infection symptoms and affecting mainly children. However, there have been reported several cases of a similar multisystem inflammatory syndrome in adults (MIS-A). We describe the case of a previously healthy 28-year-old male who presented with a clinical profile with multiorgan involvement within four weeks after confirmed SARS-CoV-2 infection, suggestive for multisystem inflammatory syndrome (MIS-A). The clinical presentation included persistent high grade of fever, gastrointestinal and mucocutaneous lesions, lymphadenopathy, elevated cardiac and inflammatory biomarkers, cytopenia and shock. This case report illustrates the wide range of presentations, diagnosis, and treatment modalities of multisystem inflammatory syndrome. The pathophysiology and the mechanisms by which SARS-CoV-2 triggers an abnormal immune response leading to MIS remain poorly understood. Better characterization of MIS-A and early recognition of MIS is important because it is associated with high mortality if left untreated.

Keywords: SARS-CoV-2; anti-IL-6 antibodies; intravenous immunoglobulin; multisystem inflammatory syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • COVID-19* / complications
  • Child
  • Humans
  • Male
  • SARS-CoV-2
  • Systemic Inflammatory Response Syndrome / diagnosis
  • Systemic Inflammatory Response Syndrome / etiology
  • Young Adult

Supplementary concepts

  • adult multisystem inflammatory disease, COVID-19 related
  • pediatric multisystem inflammatory disease, COVID-19 related

Grants and funding

This research received no external funding.